



IFW

Docket No.: MOR-0277

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In Re Application of:

Nicholas C. Nicolaides, et al.

Confirmation No.: 5311

Application No.: 10/813,502

Group Art Unit: 1653

Filing Date: March 30, 2004

Examiner: Not Yet Assigned

For: METHOD FOR GENERATING GENETICALLY ALTERED ANTIGENS

DATE OF DEPOSIT: *June 15, 2004*

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE UNITED STATES PATENT AND  
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,  
VA 22313-1450.

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with  the first or  second After Final Submission, therefore:
  - Certification in Accordance with § 1.97(e) is attached; or
  - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
  - Certification in Accordance with § 1.97(e) is attached;
  - or
  - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).

EXCEPT THAT:

- In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
  - Copies of references **1-87, 89-95** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **09/712,691**, filed **November 14, 2000** now U.S. Patent No. **6,737,268**.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Date: June 15, 2004

Felicity E. Groth  
Felicity E. Groth  
Registration No. 47,042

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b> List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. MOR-0277	Application No. 10/813,502
		Applicant Nicholas C. Nicolaides, et al.	
		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	1	Allen, D., et al., "MutS mediates heteroduplex loop formation by a translocation mechanism," <i>EMBO J.</i> , <b>1997</b> , 16(14), 4467-4476	
	2	Anders, R.F., "Part iv: Vaccines against asexual blood stages of plasmodium falciparum," <i>New Generation Vaccines</i> , 2 <sup>nd</sup> Ed., Revised and Expanded, <b>1997</b> , 1035-1055	
	3	Anderson Human gene therapy, <b>1998</b> , 25-30	
	4	Aronshtam, A., et al. "Dominant negative mutator mutations in the mutl gene of Escherichia coli", <i>Nucleic Acids Research</i> , <b>1996</b> , 24(13), pp 2498-2504	
	5	Ausiello, C.M., et al., "Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines," <i>Infection and Immunity</i> , <b>1999</b> , 67(8), 4064-4071	
	6	Baker, S.M., et al., "Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis," <i>Cell</i> , <b>1995</b> , 82, 309-319	
	7	Bell, C.J., et al., "Assignment of 30 microsatellite loci to the linkage map of <i>arabidopsis</i> ," <i>Enomics</i> , <b>1994</b> , 19, 137-144	
	8	Bishop Chromosomal insertion of foreign DNA, <b>1996</b> , 607-619	
	9	Bjornson, K., et al., "Modulation of MutS ATP hydrolysis by DNA cofactors," <i>Biochemistry</i> , <b>2000</b> , 39, 3176-3183	
	10	Bork, <i>Genome Research</i> , <b>2000</b> , 10, 398-400	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. MOR-0277	Application No. 10/813,502
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Nicholas C. Nicolaides, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	<b>11</b>	Bork, <i>Trends in Genetics</i> , 1996, 12, 425-427
	<b>12</b>	Boyce, T.G., et al., "Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults," <i>Vaccine</i> , 2001, 19, 217-226
	<b>13</b>	Brenner, <i>Trends in Genetics</i> , 1999, 15, 132
	<b>14</b>	Bronner C.E., et al., "Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer," <i>Nature</i> , 1994, 368, 258-261
	<b>15</b>	Brostoff, S., "The development and use of T cell receptor peptide vaccines," <i>Immun. Of Proteins and Peptides VIII</i> , 1995, 249-254
	<b>16</b>	Cascalho M, et al. "Mismatch repair co-opted by hypermutation", <i>Science</i> , 1998, 279(20), pp 1207-1210
	<b>17</b>	Chakravarti, D. et al., "Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: The role of apurinic sites", <i>Proc. Natl. Acad. Sci. USA</i> , October 1995, Vol. 92, pp. 10422-10426
	<b>18</b>	Corbel, M.J., "Reasons for instability of bacterial vaccines," <i>Dev. Biol. Stand.</i> , 1996, 87, 113-124
	<b>19</b>	Culligan, K.M., et al., "DNA mismatch repair in plants," <i>Plant Physiol.</i> , 1997, 15, XP-002099372, 833-839
	<b>20</b>	Devos, R., et al., "Molecular cloning of human interleukin 2cDNA and its expression in <i>E. coli</i> , <i>Nucleic Acids Research</i> , 1983, 11(13), 4307-4323

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>		Docket No. MOR-0277	Application No. 10/813,502
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Nicholas C. Nicolaides, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

21	de Wind, N., et al., "Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer," <i>Cell</i> , 1995, 82, 321-330
22	Drummond, J.T., et al., "Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells," <i>Science</i> , 1995, 268, 1909-1912
23	Drummond, J.T., et al., "Cisplatin and adriamycin resistance are associated with mut $\alpha$ and mismatch repair deficiency in an ovarian tumor cell line," <i>J. Biological Chemistry</i> , 1996, 271(33), 19645-19648
24	Edelmann, W., et al., "Meiotic pachytene arrest in MLH1-deficient mice," <i>Cell</i> , 1996, 85, 1125-1134
25	Eshleman, J.R., et al., "Mismatch repair defects in human carcinogenesis," <i>Human Molecular Genetics</i> , 1996, 5, 1489-1494
26	Fishel, R., et al., "the human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer," <i>Cell</i> , 1993, 7, 1027-1038
27	Galio, L., et al., "ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex with MutS and MutL," <i>Nucleic Acids Research</i> , 1999, 27(11), 2325-2331
28	Grasso, L., "Molecular analysis of human interleukin-9 receptor transcripts in peripheral blood mononuclear cells," <i>J. Biological Chemistry</i> , 1998, 273(37), 24016-24024
29	Hamilton, S.R., et al., "The molecular basis of turcot's syndrome," <i>N. Eng. J. Med.</i> , 1995, 332(13), 839-847
30	Harfe, B.D., "DNA mismatch repair and genetic instability," <i>Annu. Rev. Genet.</i> , 2000, 34, 359-399

**EXAMINER****DATE CONSIDERED**

<b>Form PTO-1449 Modified</b>		Docket No. MOR-0277	Application No. 10/813,502
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Nicholas C. Nicolaides, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	31	Hoang, J., et al., "BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines," <i>Cancer Research</i> , 1997, 57, 300-303
	32	Honma, M., et al., "Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53-mutated human lymphoblastoid cells," <i>Mutation Research</i> , 1997, 374, 89-98
	33	Jean, M., et al., "Isolation and characterization of <i>AtMLH1</i> , a <i>MutL</i> homologue from <i>Arabidopsis thaliana</i> ," <i>Mol. Gen. Genet.</i> , 1999, 262, XP-000986138, 633-642
	34	Jiricny, J., et al., "Mismatch repair defects in cancer," <i>Curr. Opin. Genet. Dev.</i> , 2000, 10, 157-161
	35	John, T.M., "The final stages of the global eradication of polio," <i>New England Journal of Medicine</i> , 2000, 806-807
	36	Karran, P., et al., "Genomic instability and tolerance to alkylating agents," <i>Cancer Surveys</i> , 1996, 28, 69-71
	37	Kim, K., et al., "Conformationally appropriate expression of the toxoplasma antigen SAG1 (p30) in CHO cells," <i>Infection and Immunity</i> , 1994, 62(1), 203-209
	38	Kniskern, P.J., et al., "Characterization and evaluation of a recombinant hepatitis B vaccine expressed in yeast defective for N-linked hyperglycosylation," <i>Vaccine</i> , 1994, 12(11), 1021-1025
	39	Kong, Q., "PMS2-deficiency diminishes hypermutation of a $\lambda_1$ transgene in young but not older mice," <i>Molecular Immunology</i> 36, 1999, 83-91
	40	Leach, F.S., et al., "Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer," <i>Cell</i> , 1993, 75, 1215-1225

**EXAMINER****DATE CONSIDERED**

<b>Form PTO-1449 Modified</b>		Docket No. MOR-0277	Application No. 10/813,502
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Nicholas C. Nicolaides, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>41</b>	Lechmann, M., et al., "Vaccine development for hepatitis C," <i>Seminars in Liver Disease</i> , <b>2000</b> , 20(2), 211-226	
	<b>42</b>	Lipkin, S.M., et al., "MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability," <i>Nature Genetics</i> , <b>2000</b> , 24, XP-002165243, 27-35	
	<b>43</b>	Liu, T., et al., "Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer," <i>Genes, Chromosomes &amp; Cancer</i> , <b>2000</b> , 27, 17-25	
	<b>44</b>	Liu et al., "Analysis of Mismatch Repair Genes in Hereditary Non-polyposis Colorectal Cancer Patients", <i>Nature Medicine</i> , <b>February 1996</b> , 2(2), 169-174	
	<b>45</b>	Ma et al., "Dominant Negative Expression of hPMS2 Creates Isogenic Mismatch Repair Deficient Human Colon Cancer Cell Lines", <i>Proc. Am. Assoc. Cancer Res.</i> , <b>March 1998</b> , 39, p. 460 (Abstract #3130)	
	<b>46</b>	McCallum, C.M., "Targeted screening for induced mutations," <i>Nature Biotechnology</i> , <b>2000</b> , 18, 455-457	
	<b>47</b>	McLeod, R., et al., "Immunogenetics in the analysis of resistance to intracellular pathogens," <i>Current Opinion in Immunology</i> , ISSN 0952-7915, <b>1995</b> , 7, 539-552	
	<b>48</b>	Modrich, P., "Mismatch repair, genetic stability, and cancer," <i>Science</i> , <b>1994</b> , 266, 1959-1960	
	<b>49</b>	Neuberger, M., et al., "Mice perform a human repertoire," <i>Nature</i> , <b>1997</b> , 386, 25-26	
	<b>50</b>	Ngo, et al., "Computational complexity, protein structure prediction, and the levinthal paradox," <b>1994</b> , 491-495	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. MOR-0277	Application No. 10/813,502
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Nicholas C. Nicolaides, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>51</b>	Nicolaides, N.C., et al., "Analysis of the 5' region of <i>PMS2</i> reveals heterogeneous transcripts and a novel overlapping gene," <i>Genomics</i> , <b>1995</b> , <i>29</i> , 329-334	
	<b>52</b>	Nicolaides, N.C., et al., "Molecular cloning of the N-Terminus of GTBP," <i>Genomics</i> , <b>1996</b> , <i>31</i> , 395-397	
	<b>53</b>	Nicolaides, N.C., et al., "Genomic organization of the human <i>PMS2</i> gene family," <i>Genomics</i> , <b>1995</b> , <i>30</i> , 195-206	
	<b>54</b>	Nicolaides, N.C., "A naturally occurring <i>hPMS2</i> mutation can confer a dominant negative nutator phenotype," <i>Mol. Cell. Biol.</i> , <b>1998</b> , <i>18</i> (3), 1635-1641	
	<b>55</b>	Nicolaides, N.C., et al., "The jun family members, c-jun and junD, transactivate the human <i>c-myb</i> , promotor via an Ap1-like element," <i>J. Biological Chemistry</i> , <b>1992</b> , <i>267</i> (27), 19655-19672	
	<b>56</b>	Nicolaides, N.C., et al., "Positive autoregulation of <i>c-myb</i> , expression via Myb binding sites in the 5' flanking region of the human <i>c-myb</i> gene," <i>Molecular and Cellular Biology</i> , <b>1991</b> , <i>11</i> (12), 6166-6176	
	<b>57</b>	Nicolaides, N.C., et al., "Mutations of two PMS homologues in hereditary nonpolyposis colon cancer," <i>Nature</i> , <b>1994</b> , <i>371</i> , 75-80	
	<b>58</b>	Nicolaides, N.C., et al., "Interleukin 9: A candidate gene for asthma," <i>Proc. Nat. Acad. Sci. USA</i> , <b>1997</b> , <i>94</i> , 13175-13180	
	<b>59</b>	Orenstein, W.A., et al., "Measles eradication: Is it in our future," <i>Am. J. Public Health</i> , <b>2000</b> , <i>90</i> (10), 1521-1524	
	<b>60</b>	Palombo, F., et al., "Mismatch repair and cancer," <i>Nature</i> , <b>1994</b> , <i>367</i> , 417	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. MOR-0277	Application No. 10/813,502
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Nicholas C. Nicolaides, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>61</b>	Papadopoulos, N., et al., "Mutation of a <i>mutL</i> homolog in hereditary colon cancer," <i>Science</i> , <b>1994</b> , 263, 1625-1629	
	<b>62</b>	Papadopoulos, N., et al., "Mutations of <i>GTBP</i> in genetically unstable cells," <i>Science</i> , <b>1995</b> , 268, 1915-1917	
	<b>63</b>	Parsons, R., et al., "hypermutability and mismatch repair deficiency in RER+ tumor cells," <i>Cell</i> , <b>1993</b> , 75, 1227-1236	
	<b>64</b>	Parsons, R., et al., "Mismatch repair deficiency in phenotypically normal human cells," <i>Science</i> , <b>1995</b> , 268, 738-740	
	<b>65</b>	Peinado, M.A., et al., "Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1992</b> , 89, 10065-10069	
	<b>66</b>	Perucho, M., et al., "Cancer of the microsatellite mutator phenotype," <i>Biol. Chem.</i> , <b>1996</b> , 377, 675-684	
	<b>67</b>	Polaczek, P., et al., "Functional genetic tests of DNA mismatch repair protein activity in <i>Saccharomyces cerevisiae</i> ," <i>Gene</i> , <b>1998</b> , 213(1-2), 159-167	
	<b>68</b>	Polejaeva, et al., "New advances in somatic cell nuclear transfer application in transgenesis," <b>2000</b> , 117-126	
	<b>69</b>	Prolla, T.A., et al., "MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast," <i>Science</i> , <b>1994</b> , 265, 1091-1093	
	<b>70</b>	Quian, Y. et al., "Molecular events after antisense inhibition of hMSH2 in a HeLa cell line", <i>Mutation Research</i> , <b>October 12, 1998</b> , Vol. 418, pp. 61-71	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>		Docket No. MOR-0277	Application No. 10/813,502
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Nicholas C. Nicolaides, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	71	Rulicke, et al., "Special review series-gene manipulation and integrative physiology," <b>1996</b> , 589-600
	72	Russell, et al., "Structural features can be unconserved in proteins with similar folds," <b>1994</b> , 332-350
	73	Schrader, C.E., et al., "Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes," <i>J. Exp. Med.</i> , <b>1999</b> , 323-330
	74	Sela, M., "Structural components responsible for peptide antigenicity," <i>Applied Biochemistry and Biotechnology</i> , <b>2000</b> , 83, Catalytic and Superantibodies, 63-70
	75	Spampinato, C., et al., "The MutL ATPase is required for mismatch repair," <i>J. Biological Chemistry</i> , <b>2000</b> , 275(13), 9863-9869
	76	Strand, M., et al., "Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair," <i>Nature</i> , <b>1993</b> , 365, 274-276
	77	Su, S., et al., "Dispair specificity of methyl-directed DNA mismatch correction In Vitro," <i>J. Biological Chemistry</i> , <b>1988</b> , 263(14), 6829-6835
	78	Verma, et al., "Gene therapy promises, problems and prospects," <b>1997</b> , 389, 239-242
	79	Vora, K.A., et al., "Severe attenuation of the B celll immune response in Msh2-deficient mice," <i>J. Exp. Med.</i> , <b>1999</b> , 189(3), 471-481
	80	Wheeler, J.M.D., et al., "The role of hypermethylation of the <i>hMLH1</i> promoter region in HNPCC verus MSI+sporadic colorectal cancers," <i>J. Med. Genet.</i> , <b>2000</b> , 588-592
	81	Winter, D.B., et al., "Altered spectra of hypermutation in antibodies from mice deficient for the DNA mismatch repair protein PMS2," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1998</b> , 95, 6953-6958
	82	Yu, Y. et al., "Adriamycin induces large deletions as a major type of mutation in CHO cells", <i>Mutation Research</i> , November <b>1994</b> , Vol. 325, pp. 91-98

**EXAMINER****DATE CONSIDERED**

<b>Form PTO-1449 Modified</b>		Docket No. MOR-0277	Application No. 10/813,502
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Nicholas C. Nicolaides, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date March 30, 2004	Group 1653
		Confirmation No. 5311	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	83	5,885,827	03/23/99	Wabl, et al.	435	320.1
	84	5,907,079	05/25/99	Mak et al.	800	2
	85	6,146,894	11/14/00	Nicolaides, et al.	435	440
	86	6,191,268 B1	02/20/01	Liskay et al.	536	23.5
	87	6,287,862 B1	09/11/91	delCardayre, et al.	435	440
	88	6,737,268	05/18/04	Nicolaides, et al.	435	325
	89	2002/0055106	05/2002	Nicolaides, et al.	435	6
	90	2002/0068284	06/2002	Nicolaides, et al.	435	6
	91	2002/0128460	09/2002	Nicolaides, et al.	536	23

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	92	WO 97/05268	02/13/97	PCT		
	93	WO 97/08312	03/06/97	PCT		
	94	WO 99/19492	04/22/99	PCT		
	95	2 240 609	10/14/99	Canada		

**EXAMINER****DATE CONSIDERED**